Hi Allegretto Wavelight Excimer Laser System Researchers. Here is an Article from the Lumenis Company who is the sole distributor of The Allegretto Wavelight Excimer Laser System in the United States of America. It is an old article from 2003 but will be helpful in your research of what Excimer Laser will be the best for you. If I ever had to have lasik it would be with The Allegretto Wavelight Excimer Laser. I bought stock in Lumenis as soon as I read this and it has been going up ever since.
Lasik University
Enjoy the news release and happy researching!
First refractive laser to be granted concurrent approvals for myopia and hyperopia in the United States
<Lasik University
October 21, 2003 - YOKNEAM, Israel
LumenisTM Ltd. (Nasdaq: LUME) announced today that their strategic partner WaveLight Laser Technologie AG of Erlangen, Germany received marketing clearance for the ALLEGRETTO WAVETM Excimer Laser which provides treatment of myopia (nearsightedness) and hyperopia (farsightedness) from the United States Food and Drug Administration (“FDA”). The ALLEGRETTO WAVE is the first refractive laser to receive clearance for both indications with treatment ranges for myopia of up to –12 diopters and with astigmatism of up to –6 diopters. The approval for hyperopia was granted for up to +6 diopters and with astigmatism of up to +5 diopters, not exceeding a mean spherical equivalent of +6 diopters.
“Lumenis is pleased to extend its 30-year track record of pioneering groundbreaking laser systems to the ophthalmic industry by delivering the next generation of refractive technology to the U.S. market,” said Avner Raz, President and Chief Executive Officer of Lumenis. “The excellent performance and results demonstrated in FDA clinical studies we attribute to the laser’s unique ablation profile, which has the capability to achieve unparalleled clinical results in standard LASIK procedures. We believe that the ALLEGRETTO WAVE system will set a new benchmark for standard LASIK treatment in the United States and meets our goal of providing physicians with the highest quality laser products in the marketplace.”
“The FDA approval for the ALLEGRETTO WAVE is the most important milestone that we have reached this year and one of the most important ones in our overall company history. The entire team at WaveLight has devoted tremendous time and effort to make this happen,” stated Max Reindl, Founder and Chief Executive Officer of WaveLight Laser Technologie AG, in an earlier press release.
Lumenis will be the exclusive sales agent in the U.S. responsible for all sales, marketing and field service efforts required to support the ALLEGRETTO WAVE in the U.S. market, in accordance with an exclusive representative agreement with WaveLight Laser Technologie AG. Discussions are continuing regarding licensing arrangements covering the sale of the ALLEGRETTO WAVE in the United States
The existing partnership between Lumenis and WaveLight Laser Technologie AG has successfully captured significant market share of global refractive sales outside the U.S. over the last two years. FDA clearance will allow ophthalmologists to access the German-engineered laser for the first time in the United States, the world’s largest refractive surgery market.
Clinical studies evaluated by the FDA involved treating over 800 eyes with myopia and 290 eyes with hyperopia for refractive vision correction with the ALLEGRETTO WAVE at 11 U.S. clinical sites. The laser will be officially launched at this year’s annual American Academy of Ophthalmology (AAO) meeting, the largest professional conference for ophthalmologists and medical doctors for eye treatments, in Anaheim, California next month.
About WaveLight Laser Technologie AG
WaveLight Laser Technologie AG, noted since January 2003 in the Prime Standard of the German Stock Exchange, develops, produces and distributes laser systems in the field of ophthalmology, aesthetic and urology as well as industrial processing. The innovative and technologically advanced laser systems in conjunction with a broad network of distribution channels and partners are the foundation of the market success of WaveLight. Just five years after entering the market in 1996, WaveLight managed to achieve a positive business result. In the fiscal year 2002/2003 WaveLight reached revenues of 47.8 Million Euros and an EBIT of 4.4. Million Euros.
Further information about WaveLight can be found at www.wavelight-laser.com
About Lumenis
Lumenis develops, manufactures, and markets state-of-the-art proprietary laser and intense pulsed light devices. Its systems are used in a variety of aesthetic, ophthalmic, surgical and dental applications, including skin treatments, hair removal, non-invasive treatment of vascular lesions and pigmented lesions, acne, psoriasis, ENT, gynecology, urinary lithotripsy, benign prostatic hyperplasia, open angle glaucoma, diabetic retinopathy, secondary cataracts, age-related macular degeneration, vision correction, neurosurgery, dentistry and veterinary. For more information about the Company and its products log on to www.lumenis.com
If you would like to conduct more research on The Allegretto Wavelight Laser then please visit Laser Choice
Lasik University
Showing posts with label Lasik Companies. Show all posts
Showing posts with label Lasik Companies. Show all posts
The State of the Refractive Surgery Industry (Read this Article!)
Hi Folks, this is a great article from the President and Ceo of Advanced Medical Optics also the owner of the VISX Laser. (enjoy)
Nidek Laser Technolas Laser Ladar Laser Allegretto Laser Intralase Laser Hyperion Laser NearVision CK Visx Laser Mel 80 Laser Esiris Laser Laser Scan LSX Phasik
Lasik Links
James V. Mazzo, President & CEO, Advanced Medical Optics
The past year ushered in tremendous growth and excitement in the refractive surgery industry, led by new technologies and reimbursement changes that are providing doctors and patients with an increasing number of options for quality vision treatment.
The landmark event of 2005 was the Centers for Medicare and Medicaid Services' (CMS) ruling that allowed Medicare patients to pay a premium to receive a presbyopia-correcting intraocular lens (IOL). This spurred tremendous interest in new refractive IOLs launched by AMO and others. On the laser vision correction front, the global markets continued to exhibit growth, driven by new technologies and expanded treatment ranges. Industry consolidation also continued in 2005, marked by AMO's mid-year acquisition of VISX, Incorporated, the world leader in laser vision correction.
Laser Vision Correction Procedure Growth
Procedure volume for laser vision correction in the USA grew in 2005, although not at quite the rate of the previous year. In 2004, however, growth was based on a comparison against 2003, which was a slow year. Also, in 2004, FDA approvals for wavefront-guided custom LASIK energized the industry. This helped drive a significant shift in 2005 in the mix of refractive procedures, with custom accounting for about half of all procedures in the USA. Other exciting developments included the release of sophisticated iris registration technology, which allows surgeons to achieve a new level of precision in LASIK treatment alignment.
Outside the USA, laser vision correction growth was also positive. AMO is helping to drive this growth by leveraging our large global cataract structure to grow the laser vision correction platform in select markets of Asia Pacific, Europe, and Japan. These are markets poised for significant growth in overall volume and the proportion of custom procedures as international surgeons become more familiar with the clinical benefits of wavefront-guided technologies.
The Outlook for Laser Vision Correction
The future is bright for the laser vision correction market. Manufacturers continue to develop new technologies and seek expanded treatment ranges, providing surgeons with an increasing number of options to offer patients and the ability to achieve optimal outcomes. At AMO, we are focusing our resources on seeking LASIK approval for the treatment of presbyopia in mid and low hyperopes, as well as low myopes. This could ultimately give surgeons an important tool for helping the massive baby boomer population- some 76 million strong in the US alone and known for reshaping habits, styles, and attitudes towards aging -find viable alternatives to reading glasses and bifocals.
The femtosecond laser will certainly play an important role in the future of refractive surgery. Not only has this technology filled a medical and marketing need with all-laser- LASIK, but it could also help usher in use of corneal inlays.
The mechanical microkeratome also continues to play an important role in the growth of refractive surgery. These have advanced markedly in recent years and offer standard deviations that rival laser flaps. In addition, epi-LASIK features offer increased flexibility to surgeons, allowing them to make either stromal cuts, as in traditional LASIK, or lift off the epithelium and ablate on Bowmans membrane. Again, what we see is the technology expanding options for patients and surgeons.
Emergence of Refractive IOLs
In the past, cataract patients may have been satisfied if their surgery gave them distance vision unimpaired by cataracts. After surgery, they were happy to get on with life in low-power bi- or trifocals. However, today's seniors are more active, and are looking to regain the functional vision they enjoyed when they were younger and less dependent on eyeglasses. This patient need is driving the convergence of refractive and cataract surgery.
The refractive IOL market is still in its infancy but is set for explosive growth with the CMS ruling. This is giving millions of cataract patients access to presbyopia-correcting IOLs and powering a swifter migration of cataract surgeons to refractive procedures. For example, at a recent continuing education symposium at the American Academy of Ophthalmology, 42% of the nearly 600 doctors in attendance expected between 5% and 20% of their 2006 lens implants to be multifocal IOLs. Another 24% expected multifocal IOLs to represent between 21% and 50% of their implants. These responses are a clear indication of how quickly this refractive IOL market is developing.
Movement to refractive implants is also changing the doctor/patient dynamic by shifting the focus of the discussion to one of lifestyle. Doctors are spending more time with patients to ascertain how patients spend their time, whether they are avid readers, tennis players, or frequent computer users. This is important because one IOL design may be better for near vision, while another may provide better intermediate or distance vision. All this information is essential in order for the surgeon to select the specific refractive technology, or blend of technologies, that will result in the best possible outcome for that patient.
In addition, surgeons interested in adopting refractive IOLs are reevaluating their office staffing and setup to make sure they are properly positioned to educate and interact with a private-pay patient who expects a high level of personalized service.
Future of Refractive IOLs
Patient needs will continue to drive the refractive IOL market forward. Today's multifocal IOLs represent a big step forward in this evolution, but they are only the beginning. AMO and various other industry players are dedicating significant R&D resources to deliver improved IOL designs, including accommodating lenses that mimic the normal focusing movement of the natural lens and customized IOLs, which can be tailored precisely to an individual patient's specific needs.
Capturing the Presbyopic Emmetrope
Another trend to watch is the development of surgical treatments for the presbyopic emmetrope. This is a massive segment of the population that has received little attention from refractive surgery to date. However, as an industry, we are moving closer to the time when managing presbyopia surgically will be a routine procedure. Some of the options include multifocal ablation technology, conductive keratoplasty, multifocal IOLs, accommodating IOLs, and corneal inlays.
Looking Forward
This is an exciting time for refractive surgery, as new technologies are reshaping the market and providing doctors with innovations to address a full range of patients' vision care needs. The population continues to age and roughly 60% of the world has some form of refractive error. The vast majority of this vision-corrected population still relies on eyeglasses or contact lenses, with roughly 3% opting for refractive surgical procedures to date. People are motivated to have refractive surgery and willing to pay for the procedures because freedom from eyeglasses not only improves their physical appearance, but it also enhances the quality and convenience of their daily lives.
The refractive industry is a healthy one, made up of large, global companies offering large product portfolios, and smaller players specializing in single-product technologies.
Some of these companies include AMO, Alcon, Bausch & Lomb, Eyeonics, and Intralase. Combined, these companies have increased spending on research and development by roughly 20% in absolute dollars over the past 2 years. AMO has increased its R&D spending by about 50% over the past 3 years alone. These numbers speak well to the vitality of the industry and will lead to many new advancements and opportunities. Most of all, it bodes well for the doctors and the patients they serve.
Well I hope you enjoyed this article, please check back as I will keep you all posted on more Lasik Industry news. I will keep all of you as up to date on the upcoming technology as possible. Please visit www.lasik.fm to "Logon, Listen and Learn about Lasik" Take Care
Nidek Laser Technolas Laser Ladar Laser Allegretto Laser Intralase Laser Hyperion Laser NearVision CK Visx Laser Mel 80 Laser Esiris Laser Laser Scan LSX Phasik
Nidek Laser Technolas Laser Ladar Laser Allegretto Laser Intralase Laser Hyperion Laser NearVision CK Visx Laser Mel 80 Laser Esiris Laser Laser Scan LSX Phasik
Lasik Links
James V. Mazzo, President & CEO, Advanced Medical Optics
The past year ushered in tremendous growth and excitement in the refractive surgery industry, led by new technologies and reimbursement changes that are providing doctors and patients with an increasing number of options for quality vision treatment.
The landmark event of 2005 was the Centers for Medicare and Medicaid Services' (CMS) ruling that allowed Medicare patients to pay a premium to receive a presbyopia-correcting intraocular lens (IOL). This spurred tremendous interest in new refractive IOLs launched by AMO and others. On the laser vision correction front, the global markets continued to exhibit growth, driven by new technologies and expanded treatment ranges. Industry consolidation also continued in 2005, marked by AMO's mid-year acquisition of VISX, Incorporated, the world leader in laser vision correction.
Laser Vision Correction Procedure Growth
Procedure volume for laser vision correction in the USA grew in 2005, although not at quite the rate of the previous year. In 2004, however, growth was based on a comparison against 2003, which was a slow year. Also, in 2004, FDA approvals for wavefront-guided custom LASIK energized the industry. This helped drive a significant shift in 2005 in the mix of refractive procedures, with custom accounting for about half of all procedures in the USA. Other exciting developments included the release of sophisticated iris registration technology, which allows surgeons to achieve a new level of precision in LASIK treatment alignment.
Outside the USA, laser vision correction growth was also positive. AMO is helping to drive this growth by leveraging our large global cataract structure to grow the laser vision correction platform in select markets of Asia Pacific, Europe, and Japan. These are markets poised for significant growth in overall volume and the proportion of custom procedures as international surgeons become more familiar with the clinical benefits of wavefront-guided technologies.
The Outlook for Laser Vision Correction
The future is bright for the laser vision correction market. Manufacturers continue to develop new technologies and seek expanded treatment ranges, providing surgeons with an increasing number of options to offer patients and the ability to achieve optimal outcomes. At AMO, we are focusing our resources on seeking LASIK approval for the treatment of presbyopia in mid and low hyperopes, as well as low myopes. This could ultimately give surgeons an important tool for helping the massive baby boomer population- some 76 million strong in the US alone and known for reshaping habits, styles, and attitudes towards aging -find viable alternatives to reading glasses and bifocals.
The femtosecond laser will certainly play an important role in the future of refractive surgery. Not only has this technology filled a medical and marketing need with all-laser- LASIK, but it could also help usher in use of corneal inlays.
The mechanical microkeratome also continues to play an important role in the growth of refractive surgery. These have advanced markedly in recent years and offer standard deviations that rival laser flaps. In addition, epi-LASIK features offer increased flexibility to surgeons, allowing them to make either stromal cuts, as in traditional LASIK, or lift off the epithelium and ablate on Bowmans membrane. Again, what we see is the technology expanding options for patients and surgeons.
Emergence of Refractive IOLs
In the past, cataract patients may have been satisfied if their surgery gave them distance vision unimpaired by cataracts. After surgery, they were happy to get on with life in low-power bi- or trifocals. However, today's seniors are more active, and are looking to regain the functional vision they enjoyed when they were younger and less dependent on eyeglasses. This patient need is driving the convergence of refractive and cataract surgery.
The refractive IOL market is still in its infancy but is set for explosive growth with the CMS ruling. This is giving millions of cataract patients access to presbyopia-correcting IOLs and powering a swifter migration of cataract surgeons to refractive procedures. For example, at a recent continuing education symposium at the American Academy of Ophthalmology, 42% of the nearly 600 doctors in attendance expected between 5% and 20% of their 2006 lens implants to be multifocal IOLs. Another 24% expected multifocal IOLs to represent between 21% and 50% of their implants. These responses are a clear indication of how quickly this refractive IOL market is developing.
Movement to refractive implants is also changing the doctor/patient dynamic by shifting the focus of the discussion to one of lifestyle. Doctors are spending more time with patients to ascertain how patients spend their time, whether they are avid readers, tennis players, or frequent computer users. This is important because one IOL design may be better for near vision, while another may provide better intermediate or distance vision. All this information is essential in order for the surgeon to select the specific refractive technology, or blend of technologies, that will result in the best possible outcome for that patient.
In addition, surgeons interested in adopting refractive IOLs are reevaluating their office staffing and setup to make sure they are properly positioned to educate and interact with a private-pay patient who expects a high level of personalized service.
Future of Refractive IOLs
Patient needs will continue to drive the refractive IOL market forward. Today's multifocal IOLs represent a big step forward in this evolution, but they are only the beginning. AMO and various other industry players are dedicating significant R&D resources to deliver improved IOL designs, including accommodating lenses that mimic the normal focusing movement of the natural lens and customized IOLs, which can be tailored precisely to an individual patient's specific needs.
Capturing the Presbyopic Emmetrope
Another trend to watch is the development of surgical treatments for the presbyopic emmetrope. This is a massive segment of the population that has received little attention from refractive surgery to date. However, as an industry, we are moving closer to the time when managing presbyopia surgically will be a routine procedure. Some of the options include multifocal ablation technology, conductive keratoplasty, multifocal IOLs, accommodating IOLs, and corneal inlays.
Looking Forward
This is an exciting time for refractive surgery, as new technologies are reshaping the market and providing doctors with innovations to address a full range of patients' vision care needs. The population continues to age and roughly 60% of the world has some form of refractive error. The vast majority of this vision-corrected population still relies on eyeglasses or contact lenses, with roughly 3% opting for refractive surgical procedures to date. People are motivated to have refractive surgery and willing to pay for the procedures because freedom from eyeglasses not only improves their physical appearance, but it also enhances the quality and convenience of their daily lives.
The refractive industry is a healthy one, made up of large, global companies offering large product portfolios, and smaller players specializing in single-product technologies.
Some of these companies include AMO, Alcon, Bausch & Lomb, Eyeonics, and Intralase. Combined, these companies have increased spending on research and development by roughly 20% in absolute dollars over the past 2 years. AMO has increased its R&D spending by about 50% over the past 3 years alone. These numbers speak well to the vitality of the industry and will lead to many new advancements and opportunities. Most of all, it bodes well for the doctors and the patients they serve.
Well I hope you enjoyed this article, please check back as I will keep you all posted on more Lasik Industry news. I will keep all of you as up to date on the upcoming technology as possible. Please visit www.lasik.fm to "Logon, Listen and Learn about Lasik" Take Care
Nidek Laser Technolas Laser Ladar Laser Allegretto Laser Intralase Laser Hyperion Laser NearVision CK Visx Laser Mel 80 Laser Esiris Laser Laser Scan LSX Phasik
TLC Vision to buy TruVision, expand services
TLC Vision Corp. agreed to acquire TruVision, a managed-care contractor for elective health-care services, for $17.5 million in cash and stock, it said Friday.
Nidek Laser Technolas Laser Ladar Laser Allegretto Laser Intralase Laser Hyperion Laser NearVision CK Visx Laser Mel 80 Laser Esiris Laser Laser Scan LSX Phasik
Lasik Links
Salt Lake City, Utah-based TruVision's services allow insurance health plans and large corporations to offer LASIK vision surgery to members at a reduced price. The company is projected to refer more than 23,000 LASIK procedures to its provider network this year. TLC Vision said the deal gives it immediate entry into the lower-cost market.
TLC also said Friday it plans to expand its highly profitable refractive business through a new brand, called LASIK Select, which will target the "value-priced" consumer segment.
The company plans 15 LASIK Select centers to be operating by the end of 2006. Five centers, part of the TruVision acquisition, will be operating by the end of this year. LASIK Select will target markets that don't compete with TLC Vision's existing TLC Laser Eye Centers and other lower-cost competitors.
"A broadened approach allows us to reach a different refractive patient, while continuing to realize the strong earnings and cash-flow contribution from our existing TLC Laser Eye Centers," said Jim Wachtman, president and chief executive, in a statement. "For our long-term growth, this refractive expansion strategy now gives us a business model that addresses all segments of the refractive market and continues to provide superior services to our surgeons, optometrists and the LASIK patient."
The TruVision acquisition is expected to close by mid-November.
Mississauga, Ontario -based TLC Vision Corp. (NASDAQ: TLCV) has its U.S. headquarters in St. Louis.
Now there will be 3 giant National Lasik Providers competing against one another in the value price lasik market: The Lasik Vision Institute , Lasik Plus and Lasik Select
Nidek Laser Technolas Laser Ladar Laser Allegretto Laser Intralase Laser Hyperion Laser NearVision CK Visx Laser Mel 80 Laser Esiris Laser Laser Scan LSX Phasik
Lasik Links
Nidek Laser Technolas Laser Ladar Laser Allegretto Laser Intralase Laser Hyperion Laser NearVision CK Visx Laser Mel 80 Laser Esiris Laser Laser Scan LSX Phasik
Lasik Links
Salt Lake City, Utah-based TruVision's services allow insurance health plans and large corporations to offer LASIK vision surgery to members at a reduced price. The company is projected to refer more than 23,000 LASIK procedures to its provider network this year. TLC Vision said the deal gives it immediate entry into the lower-cost market.
TLC also said Friday it plans to expand its highly profitable refractive business through a new brand, called LASIK Select, which will target the "value-priced" consumer segment.
The company plans 15 LASIK Select centers to be operating by the end of 2006. Five centers, part of the TruVision acquisition, will be operating by the end of this year. LASIK Select will target markets that don't compete with TLC Vision's existing TLC Laser Eye Centers and other lower-cost competitors.
"A broadened approach allows us to reach a different refractive patient, while continuing to realize the strong earnings and cash-flow contribution from our existing TLC Laser Eye Centers," said Jim Wachtman, president and chief executive, in a statement. "For our long-term growth, this refractive expansion strategy now gives us a business model that addresses all segments of the refractive market and continues to provide superior services to our surgeons, optometrists and the LASIK patient."
The TruVision acquisition is expected to close by mid-November.
Mississauga, Ontario -based TLC Vision Corp. (NASDAQ: TLCV) has its U.S. headquarters in St. Louis.
Now there will be 3 giant National Lasik Providers competing against one another in the value price lasik market: The Lasik Vision Institute , Lasik Plus and Lasik Select
Nidek Laser Technolas Laser Ladar Laser Allegretto Laser Intralase Laser Hyperion Laser NearVision CK Visx Laser Mel 80 Laser Esiris Laser Laser Scan LSX Phasik
Lasik Links
Subscribe to:
Posts (Atom)